Cilgavimab
Modify Date: 2024-01-29 18:17:56
Cilgavimab structure
|
Common Name | Cilgavimab | ||
|---|---|---|---|---|
| CAS Number | 2420563-99-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CilgavimabCilgavimab (AZD-1061; COV2-2130) is a humanized SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection[1]. |
| Name | Cilgavimab |
|---|
| Description | Cilgavimab (AZD-1061; COV2-2130) is a humanized SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection[1]. |
|---|---|
| Related Catalog | |
| Target |
SARS-CoV-2[1][2] |
| In Vitro | Cilgavimab 和 Tixagevimab 能够同时结合到 SARS-CoV-2 刺突蛋白 (S) 受体结合域的不同、不重叠的表位，以有效中和病毒[1]。 Cilgavimab 具有较强的单克隆抗体中和活性和人 ACE2 阻断活性，IC50 为 10-150 ng/mL，并能与三聚体 S2Pecto 蛋白或单体 SRBD 蛋白结合，IC50 为 0.1-10 ng/mL[2]。 |
| In Vivo | Cilgavimab (200 μg/小鼠; 腹腔注射; 感染 SARS-CoV-2 前 1 h 处理) 保护小鼠免于体重减轻，减少病毒负担和肺部炎症水平[2]。 |
| References |
| No Any Chemical & Physical Properties |